Receptor Tyrosine Kinases Flashcards
1
Q
Enzyme coupled receptors
A
- ligand binding to receptor activates intrinsic catalytic activity
- catalytic activity associated permanently with receptor
- eg. receptor tyrosine kinases
2
Q
Receptor Tyrosine Kinases
A
- RTKs are single span transmembrane proteins with an extracellular ligand binding domain and an intracellular tyrosine kinase domain
- ligand binding results in trans-autophosphorylation of the receptor
- TM monomers are inactive RTKs
- signal protein causes dimerisation and kinase domain activation where each monomer phosphorylates each other
- trans-autophosphorylation of tyrosines generates binding sites for signal proteins
3
Q
Human RTKs
A
- 58 RTKs encoded
- variable binding domain architecture
- conserved cytoplasmic domain
- eg. EGF, NGF, FGF, insulin
4
Q
RTKs in cancer
A
- RTKs frequently over-expressed and mutated in cancer
- Trastuzumab is a monoclonal antibody that interferes with Her2 (EGF receptor)
- treats breast and stomach cancer
- Gefitinib is a tyrosine kinase inhibitor that is specific for EGF receptors
- treat cancers with over-expressed EGFRs
5
Q
Studying RTK Signalling
A
- receptor activation is commonly studied by Western blotting using anti-pTyr antibodies
- this presence is the hallmark of activation (more ligand concentration will give more pTyr)
- cellular responses can be monitored in a number of ways by quantifying DNA synthesis or observation of cellular behaviour
- first growth factors discovered by the fact that transplanted tissue contained ligand causing nerve cell growth to it
6
Q
RTK Activation
A
- RTKs activated by ligand induced proximity of kinase domains
- many RTKs are dimerised by their ligands and some are dimers on their own and proximity of the kinase domains in the RTK dimer favours trans-autophos.
- the phos. generates the binding sites for signalling proteins
7
Q
EGF Receptor
A
- EGF is a monomer
- when binding to monomeric EGF receptor, a dimerisation arm is exposed promoting EGFR dimerisation
8
Q
Insulin Receptor
A
- receptor is a covalent disulphide linked dimer of 4 chains
- insulin brings the intracellular domains together in an active form
- dimer transmits the conformational signal
- some RTKs are non covalently associated in ligand absence, some require higher order clustering, some required co-receptors
9
Q
Heparan sulphate
A
- co-receptor for fibroblast growth factor
- repeating disaccharide of N-acetylglucosamine and glucuronic acid (sulfated sugar abundant on cell surfaces)
- The signalling complex at the cell surface is believed to be a ternary complex formed between two identical FGF ligands, two identical FGFR subunits, and either one or two heparan sulfate chains.
10
Q
Insulin Receptor Kinase Activation
A
Inactive:
- autoinhibited by activation loop with Tyr1162 adopting a pseudosubstrate conformation
Active:
- activation loop no longer blocks the active site and its 3 Tyr residues are phosphorylated.
- substrate Tyr occupies the former position of Tyr1162 positioned in a way to accept the P from ATP
11
Q
Activation Loop
A
- unphosphorylated activation loop is predominantly in the inactive conformation
- small % of loop in active conformation
- if another kinase with ATP is near it may be activated
- for transphosphorylation to occur two kinase domains with the activation loop in the active conformation have to meet
- once phosphorylated in activation loop, the kinase domain is locked in the active conformation (until P is removed)
eg. FGFR kinase
- FGFR acts as enzyme and substrate
- Tyr of activation loop positioned to be phosphorylated
12
Q
EGF receptor tyrosine kinase
A
- activated allosterically
- inactive monomer with C terminal kinase domain
- activation loop is never phosphorylated (ejected out physically)
- activator kinase domain in the asymmetric EGFR dimer allosterically activates the receiver kinase
- EGFR auto-phos. occurs in the C-terminal tail and not in the activation loop
13
Q
Docking sites
A
- phosphorylated tyrosine residues are docking sites for a variety of intracellular signalling proteins
eg. PLC-y - produces IP3, diacylglycerol
- activates PKC and Ca ion release from ER
eg. Phosphoinositide 3-kinase - phosphorylates lipid head groups that are docking sites for effectors
eg. non-enzymatic adaptors - lead to GTPase Ras activatoin and downstream signalling MAP kinase pathway
14
Q
SH2 Domains
A
- recognise p-Tyr
- Src homology region 2 domains mediate pTyr binding
- SH2 domains have apolar specificity pocket for the residue in the +3 position
- contains both specificity pocket and conserved pocket for pTyr binding
- negative residue binds positive phosphate
- SH2 domains bind to phosTyr (eg. Phospholipase C-y that also activates inositol phospholipid signal pathway to activate PKC)
- modular architecture of signalling proteins enhances specificity and allows formation of multi-protein signalling complexes
15
Q
Src Tyrosine Kinase
A
- non-receptor tyrosine kinase protein that in humans is encoded by the SRC gene
- includes an SH2 domain, an SH3 domain and a tyrosine kinase domain
- c-Src phosphorylates specific tyrosine residues in other tyrosine kinases. It plays a role in the regulation of embryonic development and cell growth